Background
A recent WHO factsheet lists that in 2008, there were about 225 million cases of malaria and nearly 800,000 deaths [
1]. These deaths are largely due to
Plasmodium falciparum infection among young children from sub-Saharan Africa. Estimates about the reported deaths due to malaria in other regions of the world are highly uncertain and are likely to be much greater than the documented ones [
2]. Observation that the repeated exposures to parasite in endemic regions can lead to development of immunity has stimulated intensive efforts to search for protective antigens to develop vaccines [
3,
4]. In last half a century, a variety of strategies involving immunization with different stages of parasite has thus far not culminated in any successful vaccine [
5]. At present, malaria is curable, but excessive and non-compliant use of anti-malarial drugs, have resulted in the emergence of drug resistance that has spread very rapidly, eliminating the effectiveness of some of these drugs to cure the disease (for example chloroquine) [
6‐
10]. There is an urgent need to develop a new class of anti-malarials that can target pathways and processes distinct from the existing therapeutic agents. In the last decade,
Plasmodium genome sequencing [
11] has greatly increased the repertoire of potential drug targets and possibilities for structure based rational drug design approaches to explore and develop novel anti-malarials [
12]. Meanwhile, time tested approaches of screening compound libraries in cellular assays have yielded very promising results [
13].
A naturally occurring benzoquinone ansamycin compound, geldanamycin (GA) is a specific inhibitor of heat shock protein 90 (HSP90) [
14,
15] and is a potential anti-cancer agent [
16,
17]. As the life cycle of
Plasmodium requires two different hosts of which one is poikilotherm and other is a homeotherm, it is not surprising that a significant fraction of parasite genome (~2%) is dedicated to molecular chaperones [
18]. As heat shock proteins are critical for maintaining a functional complement of proteins in the parasite, proteins like HSP90, HSP70/HSP40 and other smaller HSPs have been the major drug targets for anti-malarials. The blockade of HSP90 function by geldanamycin (GA) has been reported to inhibit the growth of the malarial parasite
Plasmodium falciparum in in vitro cultures [
19‐
21]. Using synchronized cultures of
P. falciparum, Bhanumathy et al. observed that the geldanamycin treatment (24 h) causes specific blockade of the transition from ring to trophozoite stage in the life cycle of the parasite [
19]. On the contrary, Kumar et al. [
20] reported that the treatment of an asynchronous culture of
P. falciparum 3D7 with geldanamycin resulted in inhibition of all intra-erythrocytic stages and the parasites were destroyed in a single developmental cycle. Such a death and disintegration led to the appearance of pyknotic bodies in the GA treated cultures [
20]. Irrespective of these discrepancies, it is clear that GA is effective in inhibiting the growth of
P. falciparum in in vitro cultures of chloroquine sensitive (strain 3D7) as well as resistant (strain W2) strains. Thus, it appears to be a good candidate to develop as a novel class of anti-malarial.
In past, attempts have been made to develop geldanamycin as an anti-cancer drug. However, due to its low aqueous solubility and high hepatotoxicity [
22], efforts were directed towards development of more water soluble and metabolically stable derivatives of GA. A synthetic analogue of geldanamycin, 17-allylamino-17-demethoxygeldanamycin (17-AAG) has been through phase-I trials for cancer treatment [
23]. This experimental drug was found to have acceptable levels of hepatotoxicity. The growing evidence regarding the potential for useful anti-malarial activity by these experimental therapeutic agents and their derivatives warrants continued pre-clinical evaluation. To date, there has been no experimental work reported on the evaluation of the efficacy of geldanamycin-derivatives in curing malaria in animal model systems. This investigation was undertaken to test the anti-malarial activity of 17-AAG and a highly water soluble geldanamycin derivative, 17-N-(3-(2-(-2(3-aminopropoxy)ethoxy)propyl)pent-4-ynamide-17-demethoxygeldanamycin (17-PEG-Alkyn-GA) in an animal model system.
Methods
Materials
Chloroquine phosphate was a kind gift from BDH Industries LTD., Mumbai, India. Protease inhibitor cocktail (cat no. P2714) was obtained from Sigma-Aldrich. Swiss mice (4-6 weeks old) were provided by the animal house facility at Tata Institute of Fundamental Research, Mumbai, India. All chemicals used were of Analar grade. HRP conjugated anti-mouse IgG was from Sigma-Aldrich.
Synthesis of geldanamycin derivatives
All reagents and solvents were purchased from commercial sources and used without further purification.
1H NMR (300 and 500 MHz) and
13 C NMR (75 MHz) spectra were recorded in CDCl
3 solution on a 300 MHz spectrometer. Chemical shifts were referenced to δ 7.26 and 77.0 ppm for
1H and
13 C spectra, respectively. High-resolution mass spectra were generated at the Purdue Mass Spectrometry Facility. Thin-layer chromatography (TLC) was performed on 250
μ M and 1000
μ M silica gel plates. Flash chromatography was run using RediSep normal-phase flash columns (230-400 mesh). Geldanamycin was isolated from fermentation of
Streptomyces hygroscopicus var.
geldanus that was provided by Dr. David Newman, NCI-Frederick. The production of geldanamycin was modified from a previously established method [
14]. Briefly, 100 mL of production medium in 500 mL tribaffled flasks with silicon closures were inoculated with confluent oatmeal slants and agitated at 150 rpm in the dark at 28°C. Initial metabolite productions were monitored from days 4.0 to 7.0 for harvest using HPLC [
24]. Harvest on day 5.5 generally achieved productions of 1.01 +/- 0.29 nmoles per 5 mL. A sample of 17-
N-allyl-17-demethoxygeldanamycin (17-AAG) was prepared after the established procedure from geldanamycin [
25].
N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)pent-4-ynamide (Alkyn-PEG-amine)
To a solution containing 1 g (10.2 mmol) of 4-pentynoic acid in 20 mL anhydrous CH2Cl2 was added 2.1 g (10.2 mmol) of N,N'-Dicyclohexylcarbodiimide (DCC) and 3.1 g (30.5 mmol) of triethylamine at 25°C under N2. The reaction mixture was stirred at 25°C for 10 min, and then 6.7 g (30.5 mmol) 3,3'-(2,2'-oxybis(ethane-2,1-diyl)bis(oxy))dipropan-1-amine in 20 mL anhydrous CH2Cl2 was added. The reaction mixture was stirred at 25°C for another 3 h. The solution was filtered and concentrated under reduced pressure. The residue was loaded into 80 g flash silica gel column eluting with two volumes of 95:5 CH2Cl2-methanol. The purified product was eluted using step gradients of 10:1:1 followed by 10:1:2 methanol:NH4OH:10% NH4OAC in H2O to yield alkyn-PEG-amine 2.6 g (85%) as a colorless sticky liquid. TLC (80:10:10 methanol: NH4OH:10%NH4OAc in H2O) followed by Ninhydrin staining showed Rf = 0.37. 1H NMR (CDCl3): δ 1.32 (dt, 4H), 1.74 (m, 2H), 1.88 (m, 2H), 1.95 (m, 2H), 3.0 (t, 1H), 3.35 (t, 2H), 3.57 (s, 12H), 7.33 (s, 2H), 7.55, (s, 1H) Mass spectrum (300.2), m/z 301.19 (M + H)+.
17- N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)pent-4-ynamide -17-demethoxygeldanamycin (17-PEG-Alkyn-GA)
To a solution containing 390 mg (1.3 mmol) of Alkyn-PEG-amine in 8 mL anhydrous CH
2Cl
2 was added 81 mg (0.14 mmol) of GA at 25°C under N
2. The reaction mixture was stirred at 25°C for 4 h and to the resulting solution 30 mL CH
2Cl
2 was added, and washed with three 10-mL portions of H
2O, three 10-mL portion of saturated brine. The organic layer was dried (Na
2SO
4) and concentrated under diminished pressure. The residue was purified by chromatography on a flash column, Eluted with 98:2 methylene dichloride-methanol gave 17-PEG-Alkyn-GA as purple solid: yield 42 mg (36%); Mass spectrum,
m/z 851.03 (M + Na)
+(C
34H
48O
2 requires 828.45). A complete set of
1H and
13 C NMR data are provided as Additional file
1.
Parasite culture, treatment of infected mice, stage specific distribution counts
A lethal mouse malarial parasite, P. yoelli 17XL was cultured in six-week old Swiss mice and parasite infected red blood cells (PRBCs) were used for infecting fresh mice by intra-peritoneal injection (~106 PRBC). Parasitaemia was scored everyday by tail bleeding and preparing thin blood smears from infected mice. The infected blood smears were stained with Giemsa; about 300-400 RBCs were examined by microscopy and the infected erythrocytes were reported as the percent of the total. The pharmacological agents were dissolved in 10% DMSO or water and injected intra-peritoneal. The fractional distribution of various intra-erythrocytic asexual stages of parasites were determined by counting rings, trophozoites and schizonts and expressed in terms of percentage of total infected or parasitized RBCs (PRBC).
Challenging malaria survivor mice after drug treatment and collection of serum from immune mice
The infected mice that survived the malaria after drug treatment (17-AAG, 17-Alkyn-PEG-GA and chloroquine) were allowed to recuperate for one month after parasite clearance. Each surviving mouse was re-challenged by injecting with ~106P. yoelii 17XL PRBCs and the parasites were allowed to grow. Thin blood smears were made every day to estimate percentage parasitaemia. Some of these mice did not show disease symptoms and cleared parasitaemia completely after 21 days of parasite infection. Approximately 0.1 to 1.0 ml of blood samples were collected using capillaries and allowed to clot for 30 min at room temperature and then subjected to centrifugation for 10 min at 3000 × g. The supernatant (serum) was collected and stored at -80°C until further analysis.
To obtain parasite sensitive serum, mice were injected with lower doses of parasite (~104) to sustain the viability of mice. After 21 days of post-parasite injection, serum samples were prepared as mentioned above. Naïve serum was collected from fresh mice.
Preparation of Plasmodium yoelii cells
Plasmodium yoelii cells were prepared as described earlier [
26], with slight modification. Briefly, the mice were infected with
P. yoelii 17XL (lethal strain) and the parasites were allowed to grow until the infected red blood cells reached ≥ 30%. At this stage, 1-2 mL of blood was collected in equal volume of anti-coagulant solution (136 mM glucose, 42 mM citric acid and 75 mM Sodium citrate). Red blood cells (RBCs) were collected by centrifugation (1500 × g for 10 minutes) and washed three times with phosphate buffer saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10 mM Na
2HPO
4, 1.8 mM KH
2PO
4, pH 7.4). The RBCs were re-suspended in PBS containing 1 mM PMSF and appropriate amounts of protease inhibitor cocktail as recommended by the supplier (Sigma-Aldrich). To this suspension of infected RBCs, 0.05% saponin was added and allowed to incubate for 1 min at 37°C. The solutions were then kept at room temperature (~20°C) for 30 minutes to release the parasite from the infected RBCs. Parasite cells were collected by centrifugation at 18000 × g for 10 min and the pellets washed with PBS to remove all the hemoglobin (as judged by red color). The cell pellet was stored at -80°C until further analysis.
Preparation of parasite and RBC cell lysates
Parasite cell pellets (~200 μg) were suspended in 200 μL of PBS containing 5 mM EDTA, 1 mM PMSF and protease inhibitor cocktail (Sigma-Aldrich). After incubation on ice for 10 minutes, the cells were subjected to freeze-thaw (six cycles) by freezing in liquid nitrogen (2 minutes) and thawing at room temperature (2 minutes). These cells were then subjected to ultrasonification for 10 seconds at constant duty cycle by using Branson Sonifier 450 and then the sample was incubated on ice for 1 minute. This process was repeated six times. The cell extract was centrifuged at 100,000 × g for 30 minutes and the supernatant collected was the cytosolic fraction. Protein concentrations of the samples were estimated by measuring OD280 nm. To prepare RBC extract, ~1 mL blood was collected from mice with 0% (uninfected), ~3% or ~30% parasitaemia in equal volume of anticoagulant. RBCs were collected by centrifugation and were lysed by using 0.05% saponin as mentioned above. The supernatant obtained by centrifuging of the lysed RBCs at 14000 × g was collected as RBC extract. Protein concentration of sample extracts was measured at OD280 nm.
SDS-PAGE and Western blotting
SDS-PAGE and Western blotting was performed as described earlier [
27]. Typically 20 μg of cellular (parasite or RBC) protein extracts were analyzed using a 12% SDS-gel and visualized with silver stain or transferred to a PVDF membrane for Western blotting using Bio-Rad Trans-Blot Semi-Dry Transfer Cell. The blots were probed by using various anti-sera (1:1,000 dilution in 1× PBS), followed by secondary HRP conjugated anti-mouse IgG (Sigma-Aldrich) used at 1:1,000 dilutions.
Discussion
Geldanamycin is a benzoquinone ansamycin antibiotic that exerts its pharmacological effects by binding to the ATP site of HSP90 and interfering with its chaperoning functions. HSP90 is a ubiquitous molecular chaperone critical for the folding, assembly and activity of the signaling proteins that promote the survival and the growth of dividing cells [
17,
30‐
33]. Binding of GA to HSP90 results in dissociation of chaperone-client protein complexes and induces the degradation of client proteins. It is believed that such destabilization of client proteins (like raf, Src, Lck, Wee1, Mek, Cdk4, Src, Ck2, Akt, ErbB2 etc.) is responsible for the anti-mitotic and anti-tumor activity of the drug. As geldanamycin is highly hepatotoxic, a less toxic derivative of geldanamycin, 17-AAG was tested in Phase-I clinical trials as an anti-tumor agent [
34‐
36].
As homologs of mammalian HSP90 are present in most pathogens, there is a possibility of GA emerging as a broad spectral anti-parasitic agent. Effects of inhibiting the functional activity of HSP90 using geldanamycin have been investigated on few pathogens. In
Leishmania donovani, it is known that transition from insect stage promastigote to pathogenic mammalian stage, the amastigote is triggered by the rise in ambient temperature. Inactivation of HSP90 by GA mimics the temperature-induced differentiation from promastigote to amastigote. However, GA treatment of cultured promastigotes induced a growth arrest [
37,
38]. Macro-filaricidal activity of GA against cat and dog filaria has also been reported [
39]. Recent observations about the ability of GA to kill adult male and female worms of
Brugia malayi (that causes lymphatic filariasis] and
Schistosoma japonicum (that causes schistosomiasis) suggests possibilities of wider therapeutic potential of this drug [
40]. GA resistant homolog of HSP90 has been reported in nematode
Caenorhabditis elegans[
41,
42] raising the possibility for the quick emergence of resistance against the drug.
As mentioned earlier, anti-plasmodial activity of geldanamycin has been investigated using
Plasmodium cultures [
18‐
21]. In the experiments reported here, these studies have been extended to an animal model and tested the anti-malarial potential of this drug. The two derivatives of geldanamycin (17-AAG & 17-PEG-Alkyn-GA) that were tested here, show anti-malarial activity and injection of two doses of 300 nmoles each per mouse were sufficient to clear the parasites (Figure
2). Detailed examination of distribution of parasites in various intra-erythrocytic stages (rings, trophozoites and schizonts) in drug treated and untreated (control) mice showed that in the treated group ring stage parasite persists resulting in the fractional increase of rings as compared to trophozoite. Such a distribution can arise if the drug treatment blocks the transition from ring to trophozoite stage. Infected erythrocytes with the blocked ring stage parasites may eventually haemolyse, releasing the parasite in the host circulatory system. Immune response to such released parasites may result in robust antibody response that conferred immunity to subsequent parasite challenges. The ability of the geldanamycin to block stage transition in the parasite life cycle appears to be equivalent to immunization with an attenuated strain of a pathogen. Attenuated
Plasmodium sporozoites prepared by irradiation [
43] or genetic manipulation [
44] are known to induce immunity. The sera collected from geldanamycin derivative-treated animals exhibited reactivity against most of the parasite proteins indicating a robust humoral response. Such sera have proved to be very useful reagent for the detection of unknown parasite proteins in analytical experiments.
For malaria vaccine development, efforts have been made to target liver, blood and/or sexual transmission stages using conventional vaccine approach of exposing the host to relevant antigens. A compilation of different antigen formulations and evaluations of field trials can be found at WHO site [
45]. Despite these efforts, there is currently no licensed, effective malaria vaccine. It is clear that for the purpose of malaria elimination, vaccines with much better efficacies are required [
46]. An emerging approach to counteract the immune-modulating effects of the parasite is to co-administer the antigens along with sub-optimal doses of immune-modulating anti-malarial drugs [
47,
48]. The approach involves administration of virulent
Plasmodium with sub therapeutic dose of an anti-malarial sufficient to contain the growth of the parasite to prevent symptoms while allowing induction of a protective immune response [
49,
50]. Robust immunity observed here in GA treated mice against a lethal strain of
P. yoelii suggests that this drug can be a potential candidate for co-administration with pathogen for the induction of immunity.
As mentioned above, clearance of parasite in geldanamycin treated mice showed sequential changes in infectivity from mature red blood cells to reticulocytes. This change in invasion specificity was also associated with loss of virulence and self-resolution of infection. Many host and parasite factors may influence such transitions between virulent and non-virulent states of the parasite. Genetic polymorphism involving a single amino acid substitution in
P.
yoelii erythrocyte binding-like protein (
Pyebl) has been reported to be one such factor [
51‐
53]. Similar changes in invasion specificity for
P. yoelii (from mature rbcs to reticulocytes) were observed in experiments where immune protection conferred by
P. falciparum enolase was investigated (unpublished data). As strong host mounted immune responses occurred in HSP90 inhibitor treated animals, it could be directly associated with the cause of preferential invasion of reticulocytes. It is possible that the observed change in host cell invasion specificity in response to geldanamycin treatment may have arisen due to a point mutation as reported earlier [
52]. Since this change in invasion specificity (from normocytes to reticulocytes) of
P. yoelii 17XL occurred in all the drug treated mice, it is highly unlikely that it can be due to a mutation in
Pyebl[
52]. As this change in specificity of invasion is associated with the slow growth as well as loss of virulence in the parasite, it is expected that the expressed proteomes of the normocyte invading and the reticulocyte invading parasites may have significant differences. It may be interesting to compare expressed proteomes from these two states (normocyte invading and reticulocyte invading) of
P. yoelii 17XL to identify the molecular players that participate in determining the host cell invasion specificity and virulence.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
RM: Performed all the experiments and analyzed the data. ZDX: Synthesized 17-AAG and 17-PEG-Alkyn-GA. AKHW: Characterized the structure of 17-PEG-Alkyn-GA by NMR. VJD: Conceived the idea of synthesizing 17-PEG-Alkyn-GA, helped in drafting the manuscript. GKJ: Conceived the study, planned the experiments, interpreted the results and wrote manuscript. All authors read and approved the final manuscript.